Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study

An investigational vaccine helped the immune strategy admit and respond to mutations that thrust astir pancreatic cancers, according to results from a randomized signifier 2 objective proceedings led by Mayo Clinic researchers. The findings, published successful Nature Medicine, volition assistance researchers plan a larger signifier 3 objective trial.